| |
|
| |
 |
| |
| |
|
| Name of the Company |
Ecron Acunova |
| |
|
| URL |
www.ecronacunova.com |
| |
|
| Company Evolution |
Public Limited Company |
| |
|
Leadership |
Global: D. A. Prasanna, Chairman
Global: Lalit Mahapatra, Chief Financial Officer
Europe & America: Anders Malm, CEO Europe |
| |
|
Business Headquarters & Contact |
Asia: Bangalore, India +91 80 6691 5700
Europe: Frankfurt, Germany +49 69 66 80 300
US: Princeton, New Jersey +1 973 396 2742 |
| |
|
| Global Office Locations |
Amsterdam, Bangalore, Bangkok, Bergamo, Berlin, Copenhagen, Espoo, Frankfurt, Kiev, Constance, Lund, Mangalore, Manipal, Moscow, Prague, Princeton NJ, Singapore, Villefranche de lauragais, Warsaw |
| |
|
No. of Employees |
379 including 70 MD/Ph D’s/physicians |
| |
|
Clients |
Leading organisations in the fields of biotech, pharma, device, diagnostic and nutrition from United States, Europe, Japan, India, China, Canada, and Israel. |
| |
|
|
Value to Clients |
 |
Audited by global regulators and conduct studies to meet regulatory guidelines of US FDA, EMEA, MHW, Health Canada, TGA, MCC, DCGI, SFDA etc. |
|
BABE labs are US FDA GDUFA identified |
|
Quality standards conform to ICH GCP, GLP, ISOand applicable national guidelines. |
|
Delivering high quality on time within budget with personalised services through an intelligent combination of local experience and global expertise. |
|
Competence based on 25 years experience with established presence in Europe, Asia and America facilitating deep regional knowledge. |
|
Access to pool of patients and volunteers (including treatment-naïves) in Asia, East Europe and Latin America. |
|
| |
|
Services |
|
Clinical Trials Phase II-IV |
|
Early development PhI, BA/BE, PK/PD |
|
Non-interventional Studies |
|
Central Lab |
|
Clinical Data Management and Biostatistics |
|
Medical Writing |
|
Pharmacovigilance |
|
Regulatory Affairs |
|
Strategic Consulting |
|
|
|
